Market Place
Sourcing Support
Stada Reports Strong Earnings, CEO Tempers Sale And IPO Expectations
28 Aug 2024 //
FIERCE PHARMA
STADA And Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar In EU
22 Jul 2024 //
GLOBENEWSWIRE
Alvotech and STADA add to strategic alliance through denosumab partnership
12 Jun 2024 //
PRESS RELEASE
Calliditas Partner STADA Gets CHMP Nod For Kinpeygo In IgA Nephropathy
31 May 2024 //
PR NEWSWIRE
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
STADA and Alvotech Secure Approval for Uzpruvo
10 Jan 2024 //
GLOBENEWSWIRE
Germany`s Stada has spun off Russian business - newspaper
23 Dec 2023 //
REUTERS
STADA and Alvotech receive positive CHMP opinion for ustekinumab biosimilar
10 Nov 2023 //
GLOBENEWSWIRE
STADA & Calliditas announce filing for full marketing authorization of Kinpeygo
28 Sep 2023 //
PR NEWSWIRE
Stada`s Kinpeygo (budesonide) Receives Approval in Europe
21 Aug 2023 //
EMA
Stada in `exploratory` phase of potential sale: CEO
15 Aug 2023 //
FIERCE PHARMA
Stada`s Kinpeygo (budesonide) Receives Approval in Europe
17 Jul 2023 //
EMA
Stada is acquiring additional brands from Sanofi
13 Jul 2023 //
PRESS RELEASE
STADA Arzneimittel`s Ximluci (Ranibizumab) Receives Approval in Europe
20 Jun 2023 //
EMA
STADA announces US FDA approves Norbitec biotech facility in Uetersen
27 May 2023 //
PHARMABIZ
Advent, CVC Are Among Suitors for €3 Billion Viatris OTC Assets
10 Feb 2023 //
BLOOMBERG
EMA Confirms Acceptance of Application for AVT04, Proposed Biosimilar to Stelara
10 Feb 2023 //
STADA
STADA, Xbrane get UK MHRA marketing approval for Ximluci biosimilar Lucentis
19 Jan 2023 //
PHARMABIZ
Stada appoints Boris Döbler as chief financial officer
03 Jan 2023 //
PHARMABIZ
With boost from Romania, Stada breaks ground on $50M plant
28 Nov 2022 //
FIERCEPHARMA
Stada to place $50M+ investment in a new facility in Romania
28 Nov 2022 //
ENDPTS
Stada`s Kinpeygo (budesonide) Receives Approval in the Europe
23 Nov 2022 //
EMA
Stada and Xbrane gain EU approval for biosimilar Ximluci
11 Nov 2022 //
PHARMATIMES
Stada Arzneimittel`s Hukyndra (adalimumab) Receives Approval in the Europe
28 Sep 2022 //
EMA
Alvotech, Stada introduce Hukyndra, a biosimilar to adalimumab in Switzerland
23 Sep 2022 //
PHARMABIZ
Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland
22 Sep 2022 //
GLOBENEWSWIRE
Stada introduces Kinpeygo in European markets to treat primary IgA nephropathy
21 Sep 2022 //
PHARMABIZ
Calliditas` partner STADA launches the first medicine authorized in the EU
20 Sep 2022 //
PRNEWSWIRE
STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar
16 Sep 2022 //
STADA
STADA and Alvotech broaden European patients’ options by launching Hukyndra
09 Jun 2022 //
BUSINESSWIRE
Teva launches Revlimid generic, the first to do so in U.S.
08 Mar 2022 //
FIERCEPHARMA
Sandoz launches generic oncology treatment in Europe
19 Feb 2022 //
PMLIVE
Crescita Therapeutics and STADA Enter Exclusive Licensing Agreement for Pliaglis
18 Aug 2021 //
BUSINESSWIRE
STADA & Sanofi strike consumer healthcare distribution agreement in EU
27 Jul 2021 //
PRESSEPORTAL
STADA & Sanofi strike consumer healthcare distribution agreement in EU
27 Jul 2021 //
PRESSEPORTAL
STADA and Midas Pharma: Driving procurement forward together
18 Dec 2020 //
PRESS RELEASE
STADA and PharmaMar sign agreement to commercialize Yondelis®
17 Nov 2020 //
ZAWYA
European Company STADA enters exclusive Medical Partnership MediPharm Labs
05 Oct 2020 //
STADA
STADA expands specialty footprint through acquisition of innovative therapy
03 Oct 2020 //
PRESSRELEASE
STADA expands specialty footprint through acquisition of innovative therapy
02 Oct 2020 //
PRESS RELEASE
STADA‘s US partner Supernus submits NDA for apomorphine infusion pump
15 Sep 2020 //
PRESS RELEASE
